title: The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients.
authors.forename: T
authors.initials: T
authors.lastname: Baba
authors.forename: K
authors.initials: K
authors.lastname: Shimada
authors.forename: S
authors.initials: S
authors.lastname: Neugebauer
authors.forename: D
authors.initials: D
authors.lastname: Yamada
authors.forename: S
authors.initials: S
authors.lastname: Hashimoto
authors.forename: T
authors.initials: T
authors.lastname: Watanabe
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D016228:Endothelial Growth Factors / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008222:Lymphokines / Q000097:blood*; D008687:Metformin / Q000627:therapeutic use*; D000077205:Pioglitazone; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D016228:Endothelial Growth Factors; D007004:Hypoglycemic Agents; D008222:Lymphokines; D013844:Thiazoles; D045162:Thiazolidinediones; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D008687:Metformin; D000077205:Pioglitazone